Michihiko Kawahara, Hatsue Fujino, Yasutoshi Fujii, Atsushi Ono, Tomokazu Kawaoka, C. Nelson Hayes et al. Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression. // Clinical Journal of Gastroenterology. – 2026. – DOI: 10.1007/s12328-026-02329-w. – URL: https://doi.org/10.1007/s12328-026-02329-w
Michihiko Kawahara, Hatsue Fujino, Yasutoshi Fujii, Atsushi Ono, Tomokazu Kawaoka, C. Nelson Hayes, Masataka Tsuge, Tetsuya Nakagiri, Koji Arihiro, & Shiro Oka (2026). Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-026-02329-w
Michihiko Kawahara, et al. “Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression.” Clinical Journal of Gastroenterology, 2026. doi:10.1007/s12328-026-02329-w.
@article{Kawahara2026,
title = {Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression},
author = {Kawahara, Michihiko and Fujino, Hatsue and Fujii, Yasutoshi and Ono, Atsushi and Kawaoka, Tomokazu and Hayes, C. Nelson and Tsuge, Masataka and Nakagiri, Tetsuya and Arihiro, Koji and Oka, Shiro},
journal = {Clinical Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s12328-026-02329-w},
url = {https://doi.org/10.1007/s12328-026-02329-w}
}